已发表论文

AP1S1 在乳腺癌中的过表达及其临床意义

 

Authors Zheng D, Fu W, Jin L, Jiang X, Jiang W, Guan Y, Hao R

Received 13 November 2021

Accepted for publication 24 March 2022

Published 16 April 2022 Volume 2022:14 Pages 1475—1492

DOI https://doi.org/10.2147/CMAR.S346519

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Beicheng Sun

Purpose: To explore the mechanism of AP1S1 in breast cancer.
Methods and Results: In different datasets, we found that AP1S1 is more highly expressed in breast tumors, which was furthermore verified in our local cohort.Immune infiltration analysis showed that AP1S1 was related to a variety of immune cells. The higher AP1S1 expression was negatively correlated with a variety of immune infiltrating cells, suggesting that AP1S1 may affect cellular immunity.Clinical analysis showed that patients with higher AP1S1 expression had higher estrogen receptor gene expression and were more prone to distant metastasis and lymph node metastasis.The overall survival rate, disease-specific survival rate, and progression-free interval time were worse in the group with higher AP1S1 expression. AP1S1 may be a potential oncogene of breast cancer, and overexpression is related to the poor prognosis of breast cancer.Therefore, a nomogram was constructed, along with correlated gene analysis and functional analysis to further explore the carcinogenic mechanism, practical clinical issues, and value of AP1S1.
Conclusion: AP1S1 is a potential oncogene of breast cancer.
Keywords: breast cancer, AP1S1, immune infiltration, prognosis, oncogene